GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

CVRx (CVRX) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is CVRx EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, CVRx's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of CVRx's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Medical Devices subindustry, CVRx's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CVRx's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CVRx's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where CVRx's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.


CVRx  (NAS:CVRX) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

CVRx EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of CVRx's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

CVRx (CVRX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)
Comparable Companies
NNOX SILK TCMD SENS CERS RCEL ARAY BVS LUNG ALUR ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445
Website
https://www.cvrx.com
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Executives
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro officer: Chief Marketing Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes director 2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain director C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer officer: SVP, U.S. Sales 9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P 10 percent owner
Nea Partners 10 L P 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo director 100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim officer: Chief Financial Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall officer: Chief Strategy Officer and Sec 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding officer: VP of Reg. Affairs and QA 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle officer: VP of Global Clinical Research 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared director, officer: Chief Executive Officer 9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445